No, There Is No Reason to Start Bupropion ER and SR Formulations at the Same Time
You should never prescribe bupropion extended-release (ER/XL) and sustained-release (SR) formulations simultaneously. This would constitute dangerous duplicate therapy with the same active ingredient, significantly increasing seizure risk and other adverse effects.
Why This Is Contraindicated
Duplicate Active Ingredient
- Bupropion ER (XL) and SR formulations contain the identical active ingredient—bupropion hydrochloride—and differ only in their release kinetics 1.
- The FDA explicitly warns against using bupropion products in combination with each other, including combinations of XL with SR, or with immediate-release formulations, or with ZYBAN (the smoking cessation formulation) 1.
- All three formulations (IR, SR, and XL) are bioequivalent in terms of systemic exposure to bupropion, meaning they deliver the same total drug exposure despite different dosing schedules 2, 3.
Seizure Risk Amplification
- Bupropion lowers the seizure threshold in a dose-dependent manner 1.
- Combining formulations would create excessive total daily bupropion exposure, dramatically increasing seizure risk beyond acceptable levels 1.
- The maximum recommended dose is 450 mg/day for SR and 450 mg/day for XL—combining formulations would exceed safe dosing limits 1.
Correct Formulation Selection
Choose One Formulation Based on Dosing Convenience
- Bupropion XL (extended-release): Dosed once daily in the morning, with starting dose of 150 mg, increasing to target of 300 mg after 4 days 1.
- Bupropion SR (sustained-release): Dosed twice daily, with starting dose of 150 mg once daily for 3 days, then 150 mg twice daily 4, 1.
- Both formulations have equivalent efficacy for depression and similar adverse event profiles 5, 2.
Switching Between Formulations
- When switching from SR to XL (or vice versa), use the same total daily dose when possible 1.
- For example, a patient on bupropion SR 150 mg twice daily (300 mg total) can switch to bupropion XL 300 mg once daily 1.
- There is no need for a washout period when switching between formulations since they contain the same active ingredient 1.
Clinical Considerations for Formulation Choice
Patient-Specific Factors
- XL formulation advantages: Once-daily dosing improves adherence; reduced risk of insomnia since the second dose is eliminated 4.
- SR formulation: May be preferred if dose adjustments are needed or in patients with renal/hepatic impairment requiring split dosing 1.
- Research demonstrates therapeutic equivalence between XL and SR for both depression and smoking cessation, with similar side effect profiles 5, 2.
Special Populations
- In moderate to severe hepatic impairment (Child-Pugh 7-15), maximum dose is 150 mg every other day for XL 1.
- In renal impairment (GFR <90 mL/min), consider reducing dose and/or frequency for either formulation 1.
Common Pitfall to Avoid
The most critical error is prescribing both formulations together, which represents duplicate therapy with serious safety implications. Always verify that patients are not already taking another bupropion-containing product (including ZYBAN for smoking cessation, WELLBUTRIN in any formulation, or APLENZIN) before initiating treatment 1.